INTRODUCTION Patient education is crucial for improving disease outcomes in atopic dermatitis (AD). This review aims to summarize evidence about the effectiveness of educational programs for parents of pediatric AD patients. METHODS PubMed and Embase (inception to Feb 2020) were searched and randomized controlled trials (RCTs) in English were included. Risk of bias was assessed using Cochrane risk of bias tools and quality of evidence was assessed by Grading of Recommendations Assessment, Development and Evaluation (GRADE). Pooled standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated for the disease severity instrument (Scoring of Atopic Dermatitis, SCORAD) and quality of life (QoL) instruments using the random-effects model. RESULTS A total of 13 RCTs were included in the systematic review. The meta-analysis of SCORAD contained seven studies with a total of 1853 patients. The reduction in disease severity (SCORAD) was larger in the treatment group (SMD = - 8.22, 95% CI = - 11.29, - 5.15; P  less then  0.001; I2  =  78.6%). Subgroup analyses revealed that the association was modified by the frequency of sessions (P for Cochran Q   less then  0.01) and the duration of follow-up (P for Cochran Q    less then  0.01). No significant effect-modification was observed for disease severity and borderline significance was observed for session delivery (individual vs group session). The pooled effect sizes for QoL measures including Dermatitis Family Index (SMD = - 0.65, 95% CI = - 1.49, 0.18), Children's Dermatology Life Quality Index (SMD = - 1.61, 95% CI = - 3.76, 0.55; I2= 89.0%) and Infants' Dermatology Quality of Life Index (SMD = 0.30, 95% CI = - 1.04, 1.63; I2= 63.1%) were not significant. CONCLUSIONS Structured patient education is beneficial and should be implemented for the management of AD patients. However, an optimal delivery mode needs to be determined.INTRODUCTION Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis through 5 years. METHODS Data were integrated from the UNCOVER-1 and UNCOVER-2, randomized, double-blinded, phase-3 trials. Patients who continuously received the labeled ixekizumab dose, were static Physician's Global Assessment (sPGA) (0,1) responders at Week 12 and completed 60 weeks of treatment could enter the long-term extension (LTE) period. Patients could escalate to every-2-week dosing per investigator opinion. Efficacy and health outcomes included proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75/90/100, sPGA (0,1) and (0), absolute PASI ≤ 5/ ≤ 3/ ≤ 2/ ≤ 1 and Dermatology Life Quality Index (DLQI) (0,1). Results exclude patients who escalated to every-2-week dosing. A modified non-responder i consistent with previous data in patients with moderate-to-severe plaque psoriasis through 5 years of treatment. TRIAL REGISTRATION ClinicalTrials.gov identifier, UNCOVER-1 NCT01474512, UNCOVER-2 NCT01597245.PURPOSE To prospectively evaluate the value of whole-body cancer screening with multiple modalities including FDG-PET in a healthy population. METHODS The study was conducted in 1197 healthy individuals aged ≥ 35 years at enrollment between August 2003 and July 2004. All participants were scheduled to receive annual whole-body cancer screening five times (screening period) with subsequent long-term follow-up (follow-up period). The endpoints of the study were definitive cancer diagnosis, cancer-related death, and all-cause death. RESULTS The follow-up rate was 99.8% for the screening period and 96.2% for the follow-up period. Forty-five cancers were confirmed during the screening period (August 2003 to July 2009), and 37 of the 45 were detected by the screening. Fourteen of the 45 were PET positive. Sixteen, 5, 4, 9 and 11 cancers were confirmed after the first, the second, the third, the fourth, and the fifth (took 2 years) screening, respectively. Eight participants died, of whom five died of cancer. The raicate the potential value of this type of cancer screening.  https://www.selleckchem.com/products/lys05.html  Cancer incidence increases with aging and it has been shown that continuous screening may reduce the risk caused by the cancer progression.INTRODUCTION The aim of this study was to compare the macular and peripapillary capillary vessel density (CVD) and foveal avascular zone (FAZ) in amblyopic eyes of adults with their fellow eyes and with eyes of healthy controls using optical coherence tomography-angiography (OCT-A). METHODS A total of 34 eyes of 17 patients with anisometropic amblyopia and 80 eyes of 40 age- and gender-matched healthy controls were included. CVD in superficial (SCP) and deep retinal capillary plexuses (DCP), peripapillary region, and FAZ were analyzed by OCT-A. RESULTS The median ages were 31 years (range 20-64) in patients with amblyopia and 34.5 years (range 24-65) in healthy controls (p = 0.242). The mean FAZ area measured was 0.329 ± 0.024 mm2 in amblyopic eyes, 0.332 ± 0.025 mm2 in fellow eyes, and 0.269 ± 0.015 mm2 in control eyes (p  less then  0.05). The amblyopic eye of participants showed a decrease in CVD of SCP and DCP (p  less then  0.001, for all). The inside optic disk CVD measurements were lower in the amblyopic eyes than in the fellow eyes (p = 0.001) and healthy subjects (p = 0.015). CONCLUSION Significant differences in macular and peripapillary microvasculature were found in anisometropic amblyopic patients. The clinical significance of the results requires further investigation.PURPOSE To evaluate the self-sealing on curved single-plane clear corneal incisions (CCIs) after cataract surgery. The collapse of the anterior chamber was made by aspirating the aqueous humor in order to make curved single-plane CCI. METHODS A retrospective study was conducted at Asai Hospital in Japan. There were 189 eyes of 132 patients scheduled from February to April 2017 for single-plane CCI. There were 175 eyes of 128 patients from February to April 2018 for curved single-plane CCI. Curved single-plane CCIs were made with aqueous humor aspiration via aqueous humor pipette, and single-plane CCIs were made without the aspiration. In case of leakage of aqueous humor from the CCI at the end of surgery, sutures were used. The main outcome measure was the proportion of sutures for CCI. Secondary outcomes included CCI length and surgically induced astigmatism (SIA) magnitude. RESULTS The proportions of suture in single-plane CCI and in curved single-plane CCIs were 25.4% (48/189) and 0% (0/175), respectively (p  less then  0.